News in brief - October 2013

Other new launches, licence changes and updates relevant to general practice.

The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment  of type II diabetes.
The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment of type II diabetes.
  • Onglyza (saxagliptin) can now be prescribed as monotherapy in type II diabetes inadequately controlled by diet and exercise when metformin is contraindicated or not tolerated.
  • Adults with symptomatic anaemia associated with chronic renal failure being treated with Aranesp (darbepoetin alfa) may now receive once monthly dosing in the correction phase of treatment provided they are not undergoing dialysis.
  • Generic sildenafil tablets are now listed in intelog for the treatment of erectile dysfunction.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Femoston 1/10, Flixotide Nebules, Synalar C...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

Bite-size Espresso learning can help you top up your...